ClinicalTrials.gg
Not yet recruitingNCT06955130Updated Dec 2, 2025

Lactate and Glycerol Contribution to Gluconeogenesis

An interventional study of Glycerol and Lactate in Type 2 Diabetes, Obesity and Healthy, sponsored by Rutgers, The State University of New Jersey. Not yet recruiting. Open to participants aged 40 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-02.

Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey — 5 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Rutgers, The State University of New Jersey.

Planned enrollment
7th of 12
48 · median 54
Started
2026
with 2 others
No phase
11 of 12
4 open now
Registered
11th of 12
by date

Among the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, this one is the 7th largest by planned enrollment, is one of 3 that started in 2026, is one of 11 with no phase, and was the 11th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, or all of them as a file.
02

Study summary

A major cause of increased blood glucose levels in type 2 diabetes (T2D) is increased hepatic gluconeogenesis (GNG), as the liver converts various substrates into glucose. Two of these substrates include glycerol, a molecule from fat, and lactate, a molecule that circulates in the blood. Our previously collected data suggest that glycerol's role in this process has been underestimated, so the investigators will directly compare the carbon contribution of glycerol and lactate to new glucose production under fasting conditions in patients with and without T2D. The investigators will also assess how glucagon, a hormone that raises blood glucose levels, impacts the conversion of glycerol and lactate to glucose. Enrolled participants will undergo three separate isotope tracer infusions with serial blood collections for liquid chromatography-mass spectrometry analysis. This research could identify new therapeutic drug targets that can lower blood glucose levels more directly and effectively.

Read the detailed description

Objectives:

  1. Compare glycerol and lactate as carbon sources for GNG in humans with and without T2D.
  2. Compare the contribution of glycerol and lactate to GNG during a hyperglucagonemic state.

Hypothesis:

  1. Glycerol contributes to glucose and lactate production, while lactate is not a net carbon contributor to glucose or glycerol production.
  2. Glycerol, not lactate, potentiates the observed increases in GNG seen in T2D.
  3. Glucagon promotes greater glycerol incorporation into glucose as compared to lactate incorporation into glucose.

Study Design:

The investigators will recruit three different adult metabolic cohorts (16 per cohort): 1) Lean, defined as body mass index (BMI) \<25.0 kg/m2, and no T2D; 2) Obese (BMI ≥ 30.0 kg/m2) and no T2D; and 3) Obese (BMI ≥ 30.0 kg/m2) and with T2D. All subjects will be between the ages of 18 and 65. All subjects will perform a self-monitored overnight fast at home and then come for three separate isotope tracer infusions (13C3-glycerol, 13C3-lactate, and 13C6-glucose) with serial blood draws. Each tracer infusion will last eight hours. During the final two hours of the infusion, subjects will receive intravenous glucagon, which increases the amount of glucose the liver produces. Collected blood samples will undergo liquid chromatography-mass spectrometry (LC-MS) analysis in our laboratory. Additionally, all subjects will receive a body composition analysis via dual-energy X-ray absorptiometry (DXA).

03

Conditions studied

  • Type 2 Diabetes
  • Obesity
  • Healthy

Keywords

  • diabetes
  • glucose
04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria for All Subjects

  1. Age 40-70 years.
  2. The subject is otherwise in general good health, based on medical history and physical examination.

Inclusion Criteria for Metabolically Healthy Subjects without Obesity

  1. No evidence of T2D or prediabetes as indicated by the American Diabetes Association (ADA), i.e., \< 5.7%, fasting glucose \< 100 mg/dL, or use of glucose-lowering medications.
  2. (BMI) ≤ 24.9 kg/m2.

Inclusion Criteria for Metabolically Healthy Subjects with Obesity

  1. No evidence of T2D or prediabetes as per ADA criteria.
  2. 30.0 ≤ BMI ≤ 45.0 kg/m2.

Inclusion Criteria for T2D Subjects

  1. Evidence of T2D as indicated by ADA criteria.
  2. 6.5% ≤ HbA1c ≤ 8.0%.
  3. 30.0 ≤ BMI ≤ 45.0 kg/m2.

Exclusion Criteria for All Subjects

  1. Chronic medical conditions that may affect glucose metabolism, including active , tobacco use, infection, kidney failure, liver dysfunction, alcoholism, pancreatitis, active viral/bacterial infection, current pregnancy/lactation, anemia, severe cardiac or respiratory failure, and uncontrolled hyperlipidemia (total cholesterol ≥ 260 mg/dL or triglycerides ≥400 mg/dL).
  2. Current medical therapy that affects glucose metabolism such as , antipsychotic, or oral pills.
  3. Type 1 diabetes mellitus diagnosis and/or history of diabetic ketoacidosis.
  4. Use of weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Glycerol

    Each subject will receive labeled 13C3-glycerol.

    Drug: Glycerol

  • Experimental
    Lactate

    Each subject will receive labeled 13C3-lactate.

    Drug: Lactate

  • Experimental
    Glucose

    Each subject will receive labeled 13C6-glucose.

    Drug: Glucose

Interventions

  • Subjects will receive an infusion of glycerol and glucagon.

  • DrugLactic AcidStudies of Lactic AcidLactic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will receive an infusion of lactate and glucagon.

  • Subjects will receive an infusion of glucose and glucagon.

06

What researchers measure

Primary outcomes

  1. Carbon Contribution to Glucose Production

    Net carbon flux from glycerol and lactate to glucose will be measured using LC-MS of plasma glucose via 13C-enrichment after infusion of various metabolic tracers

    Time frame: 8 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Final data to be shared with study sponsor

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Apr 2029, 33 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 33 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 2, 2025
StartEst.
Jul 1, 2026
Primary completionEst.
Apr 30, 2029
CompletionEst.
Apr 30, 2030
Last update
Dec 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06955130
Responsible party
Ankit Shah, MD (Assistant Professor, Rutgers, The State University of New Jersey) — Principal investigator
First posted
May 2, 2025
Start date
Jul 1, 2026 (estimated)
Primary completion
Apr 30, 2029 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Dec 2, 2025

Study contacts

Ankit Shah, MD
Contact
ashah386@rwjms.rutgers.edu
7322356337
Ankit Shah, MD
principal investigator · Rutgers Robert Wood Johnson Medical School

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glycerol · Lactic Acid · Glucose

Start the discussion